2019年获中国科学技术大学博士学位；2019年-2021年先后在中国科学技术大学和德国科隆大学从事博士后研究。2021年7月起任江南大学无锡医学院教授，博士生导师，2024年7月加入合肥综合性国家科学中心大健康研究院任研究员。主要研究方向为免疫炎症与细胞死亡。以第一或通讯作者在Nat Rev Immunol、Nat Cell Biol（2篇）、Cell Rep Med和Sci Adv等国际期刊上发表SCI论文15篇，单篇论文最高被引超660次，总被引1200余次。荣获博士后创新人才支持计划和中国科学院院长优秀奖，主持多项国家及省部级基金。

课题组长期围绕炎症性细胞死亡与重大疾病展开研究，研究方向包括：

1. 炎性细胞死亡的发生和调控机制

2. 炎性细胞死亡在肿瘤、二型糖尿病、心血管疾病和神经退行性疾病中的作用机制

3. 干预炎性细胞死亡的小分子药物筛选、制备及优化

1. Huang Y, Jiang W^#, Zhou R^#. DAMP sensing and sterile inflammation: intracellular, intercellular and inter-organ pathways. Nat Rev Immunol. 2024 Apr 29.

2. Huang Q, Ru Y, Luo Y, Luo X, Liu D, Ma Y, Zhou X, Linghu M, Xu W^#, Gao F^#, Huang Y^#. Identification of a targeted ACSL4 inhibitor to treat ferroptosis-related diseases. Sci Adv. 2024 Mar 29;1013: eadk1200.

3. Luo Y*, Luo X*, Ru Y, Zhou X, Liu D, Huang Q, Linghu M, Wu Y, Lv Z, Chen M, Ma Y^#, Huang Y^#, Wang J^#. CopperII-Based Nano-Regulator Correlates Cuproptosis Burst and Sequential Immunogenic Cell Death for Synergistic Cancer Immunotherapy. Biomater Res. 2024 Jun 27;28:0039.

4. Ru Y*, Luo Y*, Liu D*, Huang Q, Zhou X, Linghu M, Luo X, Lv Z, Wu Y, Zhang H^#, Huang Y^#. Isorhamnetin alleviates ferroptosis-mediated colitis by activating the NRF2/HO-1 pathway and chelating iron. Int Immunopharmacol. 2024 Jun 30;135:112318.

5. Jin X*, Liu D*, Zhou X, Luo X, Huang Q, Huang Y^#. Entrectinib inhibits NLRP3 inflammasome and inflammatory diseases by directly targeting NEK7. Cell Rep Med. 2023 Dec 19;412:101310.

6. Huang Y, Zhou R^#. Cytosolic transfer of circulating LPS by EVs. Nat Cell Biol. 2023 Dec;2512:1729-1731.

7. Huang Y^#, Guo Y, Zhou Y, Huang Q, Ru Y, Luo Y^#, Xu W^#. Tivantinib alleviates inflammatory diseases by directly targeting NLRP3. iScience. 2023 Feb 1;263:106062.

8. Jin X, Zhou R^#, Huang Y^#. Role of inflammasomes in HIV-1 infection and treatment. Trends Mol Med. 2022 May;285:421-434.

9. Huang Y, Wang H, Hao Y, Lin H, Dong M, Ye J, Song L, Wang Y, Li Q, Shan B, Jiang Y, Li H, Shao Z, Kroemer G, Zhang H, Bai L, Jin T, Wang C, Ma Y, Cai Y, Ding C, Liu S^#, Pan Y^#, Jiang W^#, Zhou R^#. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. Nat Cell Biol. 2020 Jun;226:716-727.

10. Huang Y*, Jiang H*, Chen Y, Wang X, Yang Y, Tao J, Deng X, Liang G, Zhang H, Jiang W^#, Zhou R^#. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. 2018 Apr;104:e8689.